AI Drives Next-Generation Melanoma Immunotherapies Toward In Vivo Testing

Researchers have created a multi-neoantigen vaccine blueprint alongside de novo protein binders that achieved precise T cell–mediated melanoma cell killing in vitro, now advancing into animal safety studies.